Introduction
============

In 2015, cancer-associated mortalities in China were estimated at 2.8 million, with 4.3 million newly identified cases, the most common of which being lung cancer ([@b1-ol-0-0-10265]). Non-small cell lung cancer (NSCLC) is the most commonly histologically diagnosed lung cancer, accounting for \~85--90% of cases ([@b2-ol-0-0-10265]). In the past decade, genetic and genomic profiling in NSCLC has improved considerably, and with it, the understanding of underlying molecular mechanisms of disease pathogenesis and strategies for targeted therapies ([@b3-ol-0-0-10265]--[@b5-ol-0-0-10265]). Potential inhibition targets for 60% of NSCLC cases in the form of actionable driver alterations have been identified through molecular profiling ([@b6-ol-0-0-10265]). Evidence supports the effectiveness of several of these targeted therapies, including, gefitinib \[epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)\], erlotinib (sensitizing EGFR mutations) and crizotinib \[sensitizing ALK receptor tyrosine kinase (ALK) and ROS proto-oncogene 1 receptor tyrosine kinase fusion\] ([@b7-ol-0-0-10265]).

Next-generation sequencing (NGS) is used in the field of genomic research and clinical applications ([@b8-ol-0-0-10265]). For patients with NSCLC, targeted NGS provides improved drug target screening and additional potential avenues of treatment ([@b9-ol-0-0-10265]--[@b12-ol-0-0-10265]). Due to the ever-growing number of discovered predictive markers for therapies and the limited availability of submitted tissue samples, the long-standing 'one test-one drug' paradigm is gradually being replaced by multiplexed genotyping platforms ([@b13-ol-0-0-10265]). One such platform is the FoundationOne CDx (F1CDx), which received marketing approval by the Food and Drug Administration (FDA). FICDx performs NGS-based *in vitro* diagnostics to detect genetic mutations in all solid tumor types and serves to identify potential beneficiaries for several FDA-approved targeted treatment options ([@b14-ol-0-0-10265]). With more NGS platforms being developed, standardization of reports from various test platforms is warranted ([@b15-ol-0-0-10265]).

In the present study, a total of 23 NSCLC samples, containing 21 Formalin-Fixed Paraffin-Embedded (FFPE) and two cell-free DNA (cf)DNA samples were analyzed. The coding regions of \~180 cancer driver genes were explored using The Roche Nimblegen (Roche Nimblegen, Inc.) custom-designed panel. Subsequently, the captured regions were sequenced by NGS to detect various types of mutations. Whenever available (for a total of 16 patients), the sequences were compared with exome sequences obtained from white blood cell (WBC) samples.

Materials and methods
=====================

### Specimen collection

A total of 23 patients with stage III/IV NSCLC at the time of diagnosis were included in the present study. Patients were recruited from The Second Hospital of Anhui Medical University (Hefei, China) between March 2017 and October 2017. The patients did not receive preoperative chemotherapy or radiotherapy, and those with prior TKI therapy were excluded from the study. There were 21 FFPE specimens and 2 cfDNA specimens in patients who did not have tissue samples available at presentation. All FFPE samples were independently assessed by two experienced pathologists and had a minimum tumor content of 40%. Blood samples from 16 patients were collected as controls to validate the identified germline mutations. Patient clinical data are presented in [Table I](#tI-ol-0-0-10265){ref-type="table"}. The samples were obtained from 10 males and 13 females (median age, 62 years; age range, 31--77 years). Among these patients, there was 1 smoker and 22 non-smokers.

### Nucleic acid preparation

Deparaffinization of 40 µm tissue sections was performed with 100% xylene (Sigma Aldrich; Merck KGaA, Darmstadt, Germany) followed by 100% ethanol as described previously ([@b16-ol-0-0-10265]). Deparaffinized samples were suspended in proteinase K-contained buffer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Following extraction using phenol-chloroform (Sigma Aldrich; Merck KGaA), DNA samples were treated with ethanol (Sigma Aldrich; Merck KGaA) precipitation and resuspended in deionized water. cfDNA blood collection tubes (Streck, Inc., Omaha, NE, USA) were used for the collection of 10 ml blood samples. Procurement of 1.2 ml of plasma from every patient was performed prior to cfDNA extraction using centrifugation twice (4°C; 1,600 × g for 10 min). cfDNA was isolated with the QIAamp Circulating Nucleic Acid kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s protocol. Validation of adopted protocols for the present study was obtained from previous findings ([@b17-ol-0-0-10265]). A total of 2 ml of total peripheral blood was used to process WBC DNA as a control, using a FlexiGene DNA kit (Qiagen, Inc.). Quantification of isolated DNA samples was performed using a NanoDrop spectrophotometer (Thermo-Fisher Scientific, Inc.), and by fluorimetry, which was conducted using Qubit dsDNA high-sensitivity and/or broad-range assay kits (Thermo Fisher Scientific, Inc.).

### Configuration of the somatic subpanel

The somatic cancer gene list was selected based on the following cancer-associated databases such as the Catalogue of Somatic Mutations in Cancer (COSMIC; [cancer.sanger.ac.uk/cosmic](cancer.sanger.ac.uk/cosmic)), MyCancerGenome ([www.mycancergenome.org](www.mycancergenome.org)), CancerIndex ([www.cancerindex.org](www.cancerindex.org)), FDA ([www.fda.gov](www.fda.gov)), European Medicines Agency ([www.ema.europa.eu/ema](www.ema.europa.eu/ema)), National Comprehensive Cancer Network (NCCN; [www.nccn.org](www.nccn.org)), PHARMGKB ([www.pharmgkb.org/](www.pharmgkb.org/)), MDAnderson Cancer Center ([pct.mdanderson.org](pct.mdanderson.org)), DRUGBACK ([www.drugbank.ca](www.drugbank.ca)), ClinicalTrial ([clinicaltrials.gov](clinicaltrials.gov)), Google Scholar ([scholar.google.com](scholar.google.com)) and PubMed ([www.ncbi.nlm.nih.gov/pubmed](www.ncbi.nlm.nih.gov/pubmed)) databases, studies published between 2000 and 2018.

### Configuration of the germline subpanel

A preliminary cancer gene list was built based on germline alterations linked with predisposition for hereditary cancer and sourced from the Human Gene Mutation Database ([www.hgmd.cf.ac.uk](www.hgmd.cf.ac.uk)), ClinVar ([www.ncbi.nlm.nih.gov/clinvar](www.ncbi.nlm.nih.gov/clinvar)), Online Mendelian Inheritance in Man ([www.omim.org](www.omim.org)), Genetics Home Reference ([ghr.nlm.nih.gov](ghr.nlm.nih.gov)) and Orphanet ([www.orpha.net](www.orpha.net)) databases. Filtering of the list was performed and genes were removed based on a number of criteria, including a lack of scientific evidence supporting their association with cancer. The tumor-associated genes in the FD-180 panel were listed in [Table II](#tII-ol-0-0-10265){ref-type="table"}.

### Library construction and sequencing

The Whole Exome Sequencing (WES) library was constructed using the Illumina TruSeq DNA Sample Prep kit (Illumina, Inc., San Diego, CA, USA), and targeted exome enrichment was performed using the SeqCap EZ Human Exome Library v2.0 kit (Roche Nimblegen Inc.). Library construction and targeted region enrichment for FD-180 were completed with the KAPA Hyper Prep kit for Illumina platforms (Kapa Biosystems; Roche Diagnostics, Indianapolis, IN, USA) and the SeqCap EZ Choice Library (Roche Nimblegen, Inc.), respectively. The FD-180 panel was used for the simultaneous sequencing of all exons of \~180 tumor-associated genes (data not shown).

Paired-end sequencing was performed with the Illumina X Ten or NEXT SEQ 500 sequencing instrument (Illumina, Inc.) according to the manufacturer\'s protocol, yielding \~150 bp short sequence reads. An average of \~15G of data was generated for each WES sample, accounting for 100--200X coverage of the entire exome. The average data for FD-180 target samples was 3G.

### Data analysis

Raw data were processed into a clean FASTQ output with flexbar (v3.3; <http://github.com/seqan/flexbar>) through trimming of adapter sequences and removing reads of insufficient quality (average quality score \<15). Raw reads were checked for the data quality using FASTQC (v0.11.5) (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Plots of quality scores across all bases in reads indicated that the majority of positions exhibited a quality score Q≥20. Raw reads were subsequently trimmed for adapter contamination using Trimmomatic (v0.32; [www.usadellab.org](www.usadellab.org)). Leading and trailing low-quality bases (\<3) were removed. Reads were scanned with a four-base-wide sliding window and the following bases of reads were cut when the average quality per base dropped below 15. Reads \>50 bases were selected for subsequent analysis. Paired clean reads following Trimmomatic treatment were aligned against the human genome (hg19) using Burrows-Wheelers Aligner ([@b18-ol-0-0-10265]). Genome Analysis Toolkit ([@b19-ol-0-0-10265]) was used to do base quality score recalibration, a process in which machine learning is applied to model quality score errors empirically, and the quality scores are adjusted accordingly. Analysis of the realigned BAM files, and detection of somatic single-nucleotide variants and insertions/deletions was performed using MuTect ([@b20-ol-0-0-10265]). Normal germline variants were filtered out using the Single Nucleotide Polymorphism Database (dsSNP) ([@b21-ol-0-0-10265]) or the Exome Aggregation Consortium (ExAC; [exac.broadinstitute.org](exac.broadinstitute.org)). Default parameter settings were used for all programs. In-house developed scripts were used to eliminate erroneous base calls and generate final mutations based on variant frequency (\>0.5%). The frequency of variation is equal to the ratio of the depth of the variant allele to the total depth of all alleles at the locus. Remaining variants were annotated using the ExAC and InterPro database (<http://www.ebi.ac.uk/interpro/>). Gene ontology enrichment was analyzed on the website ([www.geneontology.org](www.geneontology.org)), focusing on the genes which were mutated in \>4 primary tumor samples.

Results
=======

In order to explore the therapeutic relevance of FD-180 and improve the survival rate of patients with NSCLC, 2 cfDNA and 21 FFPE samples were studied to detect driver mutations in tumor DNA with (16 samples) or without matched WBC DNA as a control (mean sequencing depth, 98.96× WES). The average sequencing depth on the 180 target genes for the cfDNA and FFPE samples was 1,747.7X and 398.4X respectively. Q30 for all data was 86.4%, where Q scores are defined as a property that is logarithmically associated with the base calling error probabilities. Q30 means that the accuracy of base calling is 99.9% ([@b22-ol-0-0-10265]).

### Somatic variations in primary tumor

The mutational signature of NSCLC samples was dissected through inspection of the spectrum of base substitutions. All 23 samples exhibited similar point mutation spectra. Cytosine to thymine was the most frequent transversion among somatic mutations, which accounted for 45.6% in primary tumor tissues ([Fig. 1A and B](#f1-ol-0-0-10265){ref-type="fig"}).

Overall, 525 somatic mutations were detected in the 23 NSCLC samples. The primary type of mutation identified was missense mutations (82.1%; [Fig. 1C and D](#f1-ol-0-0-10265){ref-type="fig"}). Notably all the mutations reported were within the protein coding regions, as the capturing probes used in the current study were restricted to coding sequences. Variations with \>5% frequency, as reported in either the dbSNP or the ExAC database, were excluded. Mutation types and numbers were compared with the normal tissue datasets, and the median variant count among the 23 samples was 18 ([Fig. 1C and D](#f1-ol-0-0-10265){ref-type="fig"}). The high variant count in patient 1 remains unclear. Possible causes include poor living conditions and long cancer progression time prior to diagnosis.

### Implicated biological processes and molecular function

Gene Ontology ([www.geneontology.org](www.geneontology.org)) enrichment analysis was performed with 40 frequently mutated genes (genes which were mutated in \>4 primary tumor samples). 'Peptidyl-tyrosine phosphorylation', 'peptidyl-tyrosine modification', 'phosphatidylinositol-mediated signaling', 'inositol lipid-mediated signaling' and 'protein autophosphorylation' were the top five biological process of these high frequency genes in the 23 NSCLC samples ([Fig. 2A](#f2-ol-0-0-10265){ref-type="fig"}). Notably, the molecular functions of these genes included 'protein tyrosine kinase activity', 'transmembrane receptor protein tyrosine kinase activity', 'transmembrane receptor protein kinase activity', 'phosphatidylinositol 3-kinase activity' and 'phosphatidylinositol-4,5-bisphosphate-3-kinase activity' ([Fig. 2B](#f2-ol-0-0-10265){ref-type="fig"}).

### Actionable mutations with available targeted therapies

The top 20 mutated genes in the 23 tumor samples were identified by counting the frequency of mutations in different genes in the samples ([Fig. 3](#f3-ol-0-0-10265){ref-type="fig"}). EGFR, TP53, and APC were the most conmon mutated gene with a frequency of 61, 48 and 43% respectively. Among the 23 NSCLC samples, 69.57% (16/23) of the patients carried the mutations with available matched targeted therapeutic options ([Table III](#tIII-ol-0-0-10265){ref-type="table"}). This proportion is consistent with the previous study ([@b23-ol-0-0-10265]). In this study, EGFR mutations which occurred in exon 18--21 were the most common mutations carried by 14 patients. A total of 13 patients harbored the EGFR sensitizing mutations, which were recommended for first-line treatment with gefitinib, erlotinib, afatinib, dacomitinib, Icotinib or osimertinib according to the NCCN, FDA or China Food and Drug Administration (CFDA) guidelines ([@b24-ol-0-0-10265]--[@b26-ol-0-0-10265]). One of these 13 patients harbored the acquired resistance mutation EGFR p.T790M, and was amenable to third-generation EGFR inhibitors, including osimertinib, for first-line or subsequent treatment ([@b27-ol-0-0-10265]). Patient 21 carried EGFR p.746_750del and PIK3CA p.R108H mutations simultaneously ([Table III](#tIII-ol-0-0-10265){ref-type="table"}). According to previous studies, approximately 4--5% of EGFR-mutated lung cancer types with acquired resistance to EGFR-TKI therapy harbor PIK3CA mutations ([@b28-ol-0-0-10265]--[@b30-ol-0-0-10265]). A total of 2 patients harbored a KRAS p.G12C mutation, which is a common variant in NSCLC tumors ([@b31-ol-0-0-10265]). CDKN2A p.W110X was detected simultaneously with EGFR p.E746_A750del in patient 12 ([Table III](#tIII-ol-0-0-10265){ref-type="table"}).

### Germline mutations with clinical implications

A number of cancer types manifest as a result of inherited defects in key genes within the genome. These genes are a subclass among the cancer driver genes. Their function may involve tumor suppressor genes, oncogenes, genes involved in DNA repair, cell cycle control, apoptosis and angiogenesis factors ([@b32-ol-0-0-10265]). In the present study, germline mutations were identified through sequencing of the WBC DNA from patients and validated with paired tumor sample sequencing for 16 patients. The cancerous germline mutations identified in the 15 patients are presented in [Table IV](#tIV-ol-0-0-10265){ref-type="table"}. A total of 15/16 patients (93.8%) exhibited cancer driver gene mutations. A total of 57.1% of the mutations were previously reported in the ExAC database and were described as 'Uncertain significance or not provided' in the NCBI ClinVar database, whereas 42.9% were identified as *de novo* mutations.

Discussion
==========

Several single-institution studies revealed that targeted NGS permits the detection of actionable mutations in clinical lung cancer tumor samples, enabling patient selection for genotype-based therapies ([@b10-ol-0-0-10265]--[@b12-ol-0-0-10265]). The present study demonstrated the clinical utility of FD-180 profiling in NSCLC. A total of 69.6% (16/23) NSCLC samples in the present study were identified to harbor mutations with available matched targeted therapeutic options. Notably, 13 patients harbored actionable EGFR mutations, with treatment recommended. However, 3 patients may benefit from drug agents, which have not yet been approved for lung cancer. The available data indicating PIK3CA mutations that predict the response of solid tumors to phosphoinositide 3-kinase (PI3K) signaling pathway inhibitors, including everolimus ([@b33-ol-0-0-10265]) and temsirolimus ([@b34-ol-0-0-10265],[@b35-ol-0-0-10265]), remain controversial. Multiple PI3K inhibitors, including BYL719, buparlisib (BKM120), taselisib (GDC0032), and GSK2636771, are under investigation in patients with PIK3CA-mutated or PTEN-mutated solid tumors ([@b36-ol-0-0-10265]).

KRAS p.G12C has been negatively associated with progression-free survival ([@b37-ol-0-0-10265]) and decreased sensitivity of EGFR-TKIs, including erlotinib and gefitinib ([@b38-ol-0-0-10265],[@b39-ol-0-0-10265]). Currently, the role KRAS mutations serve in the selection of anticancer treatment remains unclear; however, clinical evidence suggests that KRAS-mutant tumors, specifically in lung adenocarcinoma, respond positively to selumetinib and trametinib ([@b40-ol-0-0-10265]). A phase II randomized trial indicated that a selumetinib and docetaxel combined therapy increased overall response rates and progression free survival in patients with KRAS-mutant NSCLC compared with the placebo control group ([@b41-ol-0-0-10265]). A mouse model indicated that serine/threonine kinase 11-deficient KRAS mutant NSCLC tumors were resistant to mitogen-activated protein kinase (MEK) inhibition, which may be clinically relevant ([@b42-ol-0-0-10265],[@b43-ol-0-0-10265]). In a phase I dose escalation trial with the MEK inhibitor trametinib, reductions in tumor size of 6--52% were observed in 8/22 patients with KRAS mutation-positive tumors ([@b44-ol-0-0-10265]). However, the aforementioned studies require further validation with larger sample sizes and inclusion of KRAS wild-type tumors for comparison to enhance the evidence for clinical efficacy. Therefore, the use of MEK inhibitors for treating KRAS mutation-positive tumors is only recommended in a clinical trial setting.

Somatic mutations of CDKN2A are present in various tumor types ([@b45-ol-0-0-10265]--[@b47-ol-0-0-10265]). However, currently there are no existing standard therapy options to treat tumors harboring somatic CDKN2A alterations. The loss of function mutation of CDKN2A leads to activation of CDK2/4/6, suggesting that CDK inhibitors may be beneficial for these patients ([@b48-ol-0-0-10265]). Palbociclib is a highly selective CDK4/6 inhibitor, which has demonstrated sensitivity in *in vitro* studies of renal cell carcinoma ([@b49-ol-0-0-10265]), melanoma ([@b50-ol-0-0-10265]), ovarian cancer ([@b51-ol-0-0-10265]) and breast cancer ([@b52-ol-0-0-10265]) cell lines, suggesting that this drug may be effective for the treatment of patients included in the present study.

Even though actionable genomic alterations are primarily somatically acquired, it has been reported that inherited cancer predisposition is predominantly associated with germline mutations ([@b32-ol-0-0-10265]). In this study a total of 93.8% of patients (15/16) carried germline mutations which have been previously associated with cancer. Among these 28 mutations, known and *de novo* germline mutations were identified in 57.1% (16/28) and 42.9% (12/28), respectively. Only a small proportion of NSCLC cases may be attributed to inheritance of genetic mutations ([@b53-ol-0-0-10265]). However, the results obtained in the present study suggested otherwise, indicating that the association between the identified mutations and lung cancer requires further investigation with a larger sample size.

Notably, the current study does not provide information on the long-term impact of the FD-180 gene panel on treatment outcomes, including morbidity, quality of life, disease-free survival and overall mortality. A limitation of the present study is therefore the lack of long-term follow-up to monitor these parameters. In conclusion, the present study demonstrated that the FD-180 gene panel is a robust diagnostic tool which may be used to identify targeted therapeutics for patients with NSCLC.

The authors would like to thank Mr. Paul Ma \[First Dimension Biosciences (Suzhou) Co., Ltd.,\] for his contributions in revising this manuscript.

Funding
=======

The present study was partly funded by First Dimension BioSciences (Suzhou), Co., Ltd.

Availability of data and material
=================================

The raw sequencing data are not publicly available due to information that could compromise the privacy of the research participants.

Authors\' contributions
=======================

WC and TT designed the study. HFW collected the data. CY and HLW analyzed the data. DL designed and wrote the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

The Anhui Medical University Ethics Committee approved the study and all patients have given written informed consent prior to inclusion in the project.

Patient consent for publication
===============================

All patients provided a comprehensive consent form stating that personal data may be used for academic presentation or paper presentation, while ensuring complete anonymity prior to receiving treatment.

Competing interests
===================

The authors declare that they have no competing interests.

![Statistical analyses of somatic mutations in 23 patients with NSCLC. (A) A breakdown of the observed substitution mutations. (B) Distribution of different variation types among all samples. The different colors present the base substitutions in the samples. (C) An overview of the types of mutations observed. (D) Distribution of different variation types among all samples. The different types of mutations are presented using different colors. P1-P23 present the patient ID. T, tyrosine; C, cytosine; A, adenine; G, guanine; Del, deletion; Ins, insertion.](ol-17-06-5425-g00){#f1-ol-0-0-10265}

![The biological processes and molecular function for the mutational genes in the 23 patients with NSCLC. (A) Main biological processes and gene ratio for frequently mutated genes. (B) Association between frequently mutated genes and their molecular function. Associated genes are present in the grey circles. P adjust, adjusted P-value. NSCLC, non-small cell lung cancer.](ol-17-06-5425-g01){#f2-ol-0-0-10265}

![Top 20 mutated genes in the 23 patients with NSCLC. A total of 20 genes\' name are listed. P1-P23 present the patient ID. Each type of mutation is presented by a different colour. The values (0--120) on top of the figure present the total number of all the different mutations identified in each patient. The values (22--61%) on the left present the frequency of each gene mutation among the 23 patients. The values (0--14) on the right present patient number who harbored the mutations of the listed genes. NSCLC, non-small cell lung cancer.](ol-17-06-5425-g02){#f3-ol-0-0-10265}

###### 

Overview of patient and tumor characteristics in the present study.

  Characteristics           n (%)
  ------------------------- -----------
  Sex                       
    Male                    10 (43.5)
    Female                  13 (54.5)
  Age                       
    \>60                    13 (54.5)
    ≤60                     10 (43.5)
  Smoking status            
    Smoker                  1 (4.3)
    Non-smoker              22 (95.7)
  Stage                     
    I                       9 (39.1)
    II                      1 (4.3)
    III                     6 (26.1)
    IV                      3 (13.0)
    Unknown                 4 (17.4)
  Type of specimen          
    FFPE tissue samples     21 (91.3)
    Cell-free DNA (cfDNA)   2 (8.7)
    Genomic DNA (gDNA)      16 (69.6)

FFPE, Formalin-fixed, Paraffin-embedded; cfDNA, cell-free DNA; gDNA, genomic DNA.

###### 

The gene list of FD-180 panel.

  APC       ATM      ATR      AXIN2     RECQL4    RET      RNF43     RUNX1
  --------- -------- -------- --------- --------- -------- --------- ---------
  BAP1      BLM      BMPR1A   BRCA1     SBDS      SDHA     SDHAF2    SDHB
  BRCA2     BRIP1    CDC73    CDH1      SDHC      SDHD     SETBP1    SLC2A2
  CDK4      CDKN1B   CDKN2A   CHEK2     SLX4      SMAD4    SMARCA4   SMARCB1
  CLCN7     CYLD     DDB2     DICER1    SMARCE1   SPTA1    STK11     SUFU
  EPCAM     ERCC2    ERCC3    ERCC4     TERT      TGFBR2   TP53      TP63
  ERCC5     EXT1     EXT2     FANCA     TSC1      TSC2     VHL       WAS
  FANCB     FANCC    FANCD2   FANCE     WRN       WT1      XPA       XPC
  FANCF     FANCG    FANCI    FANCL     ABL1      ABL2     AKT1      ALK
  FANCM     FH       FLCN     GALNT12   AR        ARAF     ATM       ATR
  GLA       GPC3     HNF1A    MAD2L2    BRAF      BRCA1    BRCA2     CDK12
  MAX       MEN1     MLH1     MLH3      CDK4      CDK6     CRKL      CDKN1A
  MPL       MSH2     MSH3     MSH6      CDKN2A    CHD4     CHEK2     CSF1R
  MUTYH     NBN      NF1      NF2       CTNNB1    DDR2     EGFR      ERBB2
  PALB2     PHOX2B   PIK3CA   PMS1      ERBB3     ERBB4    ESR1      FANCA
  PMS2      POLD1    POLE     PRF1      FANCB     FANCI    FANCL     FANCC
  PRKAR1A   PRKCD    PTCH1    PTEN      FANCD2    FANCE    FANCF     FANCG
  RAD50     RAD51C   RAD51D   RB1       FANCM     FBXW7    FGFR1     FGFR2
  TSC1      TSC2     XRCC2    SPOP      FGFR3     FGFR4    FRK       FYN
  MAPK1     MAPK3    MET      mTOR      GNA11     GNAQ     GRM3      HRAS
  NF1       NOTCH1   NRAS     PDGFRA    IDH1      IDH2     KDR       KIT
  PIK3CA    PIK3CD   PIK3R1   PTCH1     KRAS      LYN      MAP2K1    MAP2K2
  PTEN      PTPN11   RAC1     RAF1      RET       ROS1     SMO       

###### 

Actionable genomic alterations and implications for targeted therapeutics.

  Patient ID   Genomic alterations   Allele frequency in current study   Associated drugs                                        Implication for targeted therapeutics
  ------------ --------------------- ----------------------------------- ------------------------------------------------------- ---------------------------------------
  P3           EGFR p.747_753del     0.249                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P5           EGFR p.746_750del     0.205                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P6           EGFR p.L858R          0.382                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P7           EGFR p.745_750del     0.378                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P8           KRAS p.G12C           0.156                               Trametinib, Everolimus, Temsirolimus                    Possibly sensitive
                                                                         Gefitinib, Erlotinib, Afatinib, Icotinib                Decreased EGFR-TKI sensitivity
  P10          EGFR p.L861Q          0.206                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
               EGFR p.G719C          0.252                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P12          CDKN2A p.W110X        0.246                               Palbociclib                                             Possibly sensitive
               EGFR p.E746_A750del   0.102                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P15          EGFR p.746_750del     0.248                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P16          EGFR p.L858R          0.297                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P17          EGFR p.L858R          0.287                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P18          EGFR p.747_752del     0.14                                Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P19          EGFR p.E746_A750del   0.367                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P20          EGFR p.L858R          0.139                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
  P21          EGFR p.746_750del     0.367                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   Decreased EGFR-TKI sensitivity
               PIK3CA p.R108H        0.061                               Everolimus, Temsirolimus                                Possibly sensitive
  P22          EGFR p.L747_T751del   0.157                               Gefitinib, Erlotinib, Afatinib, Icotinib, Osimertinib   EGFR-TKI sensitive
               EGFR p.T790M          0.208                               Osimertinib                                             EGFR-TKI sensitive
  P23          KRAS p.G12C           0.464                               Trametinib, Everolimus, Temsirolimus                    Possibly sensitive
                                                                         Gefitinib, Erlotinib, Afatinib, Icotinib                Decreased EGFR-TKI sensitivity

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; KRAS, KRAS proto-oncogene, GTPase.

###### 

Germline mutations in cancer susceptibility genes in 15 patients.

  Patient ID   Gene     Amino acid change   InterPro domain                                                                                                                             Reference single nucleotide polymorphism ID number   Allele frequency in the Exome Aggregation Consortium   Allele frequency in current study
  ------------ -------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------ -----------------------------------
  P1           FANCD2   p.D662V             --                                                                                                                                          --                                                   --                                                     0.37
               SLX4     p.D1425N            --                                                                                                                                          rs766448056                                          9.05×10^−06^                                           0.58
  P11          POLE     p.F2258L            --                                                                                                                                          --                                                   --                                                     0.51
               TSC2     p.P1158S            --                                                                                                                                          --                                                   --                                                     0.47
  P14          FANCM    p.H1103P            --                                                                                                                                          rs191339110                                          8.28×10^−06^                                           0.39
  P15          PTCH1    p.T265S             --                                                                                                                                          rs201174718                                          0.0001                                                 0.51
               WRN      p.K577T             DEAD/DEAH box helicase domain; Helicase superfamily 1/2 ATP-binding domain; P-loop containing nucleoside triphosphate hydrolase             --                                                   --                                                     0.49
  P16          EXT1     p.V356L             --                                                                                                                                          --                                                   --                                                     0.47
  P19          ATM      p.A1315V            Armadillo-type fold                                                                                                                         --                                                   --                                                     0.55
               AXIN2    p.V619A             --                                                                                                                                          --                                                   --                                                     0.45
               FANCA    p.D694N             --                                                                                                                                          rs201589909                                          0.0001                                                 0.40
  P22          FANCG    p.P590A             --                                                                                                                                          rs541868979                                          9.07×10^−05^                                           0.33
               PMS1     p.R202K             Histidine kinase like ATPase C-terminal domain; Ribosomal protein S5 domain 2-type fold; Ribosomal protein S5 domain 2-type fold subgroup   rs2066459                                            0.012                                                  0.58
  P23          MSH3     p.R574Q             DNA mismatch repair protein MutS core                                                                                                       rs776668872                                          8.72×10^−06^                                           0.46
  P3           CLCN7    p.N104K             Chloride channel core                                                                                                                       --                                                   --                                                     0.58
               MLH3     p.V741F             --                                                                                                                                          rs28756990                                           0.0145                                                 0.44
               PTEN     c.-326\_-324del     --                                                                                                                                          --                                                   --                                                     0.18
               SPTA1    p.N2057S            --                                                                                                                                          rs761106571                                          5.80×10^−05^                                           0.46
  P4           FANCM    p.I552T             Helicase C-terminal; P-loop containing nucleoside triphos phate hydrolase                                                                   rs200240871                                          8.25×10^−06^                                           0.58
  P5           BLM      p.R1139Q            RQC domain; Winged helix turn helix DNA binding domain                                                                                      rs771776126                                          8.24×10^−06^                                           0.5
  P6           STK11    p.P411L             --                                                                                                                                          --                                                   --                                                     0.65
  P7           APC      p.A1753P            --                                                                                                                                          rs587781350                                          1.66×10^−05^                                           0.49
               ATM      p.D841Y             --                                                                                                                                          --                                                   --                                                     0.41
               FANCA    p.T1161K            --                                                                                                                                          rs142833057                                          3.30×10^−05^                                           0.55
               SPTA1    p.D607H             --                                                                                                                                          rs534906145                                          8.28×10^−06^                                           0.58
  P8           POLD1    p.R322H             DNA-directed DNA poly merase family B exonuclease domain; Ribonuclease H like domain                                                        --                                                   --                                                     0.39
  P9           CLCN7    p.R775H             CBS domain                                                                                                                                  rs534953229                                          0.0002                                                 0.33
               SLC2A2   p.G519E             --                                                                                                                                          rs147959014                                          0.0018                                                 0.39

-, information not available.
